Despite fewer bleeding events during cardiac surgery,<unk>  carries the risk of potential autoimmune reactions manifesting as breathlessness. Potential mechanisms for dyspnea following<unk>  treatment include: repeated binding and unbinding cycles, impaired platelet turnover, and lung sequestration or apoptosis of overloaded destructive platelets. The dyspnea risks following<unk>  treatment, suggest a common mechanism linking transfusion-related acute lung injury, dyspnea, and reversible platelet inhibition. The risk of breathlessness after intravenous<unk>  is smaller when compared with other reversible platelet P2Y12 receptor inhibitors, however, it is still significantly higher when compared to irreversible oral antiplatelet drugs or intravenous glycoprotein IIb/IIIa inhibitors; which do not increase the incidence of breathlessness at all.
Cangrelor
Cetrorelix
Riociguat
Vericiguat
Prokarin
Prasugrel
Coronaridine
Aprepitant